Also in BioCentury’s Clinical Report, an updated norovirus vaccine from Vaxart, early CML results from Enliven, and more

Plus: Verastem’s follow-on and Hangzhou Jiuyuan’s IPO plans

No black box warning and a broad label for the pediatric brain cancer therapy

Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential

Pharma outlines goals for oncology business as it moves to integrate ADC play Seagen 

Therapy will be made at the biotech’s Philadelphia facility and a nearby CDMO, with plans to serve ‘up to several thousand patients annually’

Five-year-old biotech receives April PDUFA date for pan-RAF inhibitor to treat slow-moving pediatric brain cancer